Press release
TNO Pharma (NL) - TNO PHARMA ANNOUNCES siRNA IN-VIVO TECHNOLOGY DEVELOPMENT COLLABORATION WITH MITSUBISHI PHARMA CORPORATION
Leiden, The Netherlands, September 6, 2005 - TNO, a recognized research and technology organization and Mitsubishi Pharma Corporation, a leading pharmaceutical company of Japan, announced today that they have entered into a technology development collaboration. In this project, TNO will combine its expertise in siRNA based knock-down technology with its long term experience in disease models to further characterize a set of Mitsubishi´s proprietary disease targets. Financial details of the collaboration were not disclosed."TNO is very pleased to be selected by Mitsubishi," said Renger Witkamp, Executive Director of TNO Pharma. "This partnership underlines the competitive edge of our Institute in applying siRNA in-vivo expertise with our disease model capabilities in cardiovascular & metabolic and inflammatory diseases."
"We are pleased to announce this collaboration with TNO," said Dr Nakajima, Executive Officer/General Manager of the Pharmaceutical Research Unit for Mitsubishi Pharma. "We will gain access to unique expertise that will provide us with high quality target validation data."
About TNO´s pharma activities
TNO´s pharma division is a recognized partner for the pharmaceutical and biotech industry and offers a broad array of tailor-made and value-creating expertise and services in the area of drug discovery and development. TNO offers top-level expertise in areas of: cardiovascular, metabolic, autoimmune and inflammatory diseases. Its unique disease models are supported by expert teams of international scientific reputation. In addition TNO offers a complete GLP compliant portfolio in drug safety, bio-analysis and DMPK. TNO´s pharma activities are part of TNO, the Netherlands Organisation for Applied Scientific Research. Further information can be found on: http://www.tno.nl/pharma
Contact TNO Pharma:
Renger Witkamp,
+31 30 6944844
witkamp@pharma.tno.nl
About Mitsubishi
Mitsubishi Pharma Corporation is a global research-driven pharmaceutical company targeting the therapeutic areas of cardiovascular and metabolic diseases, psychiatric and central nervous system diseases, immunological and respiratory diseases, and cancer and hepatic diseases. This company was founded by the merger between former Welfide Corporation and Mitsubishi-Tokyo Pharmaceuticals, Inc., on October 1, 2001. Mitsubishi Pharma Corporation has established a strong drug discovery infrastructure to engage in the development of innovative new drugs. www.m-pharma.co.jp
PDF version press release
http://hugin.info/135977/R/1010376/156964.pdf
The issuer is solely responsible for the content of this announcement.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release TNO Pharma (NL) - TNO PHARMA ANNOUNCES siRNA IN-VIVO TECHNOLOGY DEVELOPMENT COLLABORATION WITH MITSUBISHI PHARMA CORPORATION here
News-ID: 63 • Views: …
More Releases for Mitsubishi
Power Systems Market Latest Rising Trend & Forecast to 2026 - Top Companies Cate …
Global Power Systems Market research report gives a comprehensive outlook of the markets 2019-2026 and offers an in-depth summary of the current market status, historic, and expected way forward for the Power Systems Market. Additionally, to this, the report provides data on the restraints negatively impacting the markets growth. The report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the…
Global SCADA in Process Industries Market To 2025| Mitsubishi Heavy Industries, …
Albany, NY, 7th June : Recent research and the current scenario as well as future market potential of "Global SCADA in Process Industries Market Insights, Forecast to 2025" globally.
To present a clear research study that provides the opportunities available, the report divides the global market for SCADA in Process Industries into important segments on the basis type, application, technology, and geography. Market revenue in terms of US$ Mn for the…
Traction Transformer (Onboard) Market Global Trends, Business Growth, Emerging s …
The report provides a comprehensive analysis of the Traction Transformer (Onboard) Market by types, applications, players and regions. This report also displays the 2018-2024 production, Consumption, revenue, Gross margin, Cost, Gross, market share, CAGR, and Market influencing factors of the Semiconductors and Electronics industry in global regions.
An in-depth Traction Transformer (Onboard) Market analysis based on multiple market Frameworks such as the market size, projections on the market growth rates, market…
Global Touch Panel Cover Market 2016: Focuses on top players Mitsubishi Rayon, M …
The Touch Panel Cover research report by QY Research represents an inclusive evaluation of the Global Touch Panel Cover Market and comprises considerable insights, historical data, facts, and statistical and industry-validated data of the global market. Additionally, it consists of estimated data that is evaluated with the help of suitable set of methodologies and assumptions. The research report highlights informative data and in-depth analysis of Touch Panel Cover market and…
Global High Temperature Electrical Insulating Film Market 2017 - TORAY, DuPont, …
Report studies High Temperature Electrical Insulating Film in Global market that focuses on the top Manufacturers, Market Segment by Countries, Split by Product Types (with sales, revenue, price, market share of each type), Split by applications this report focuses on sales, market share and growth rate of High Temperature Electrical Insulating Film in each application.
This report studies the High Temperature Electrical Insulating Film market. High Temperature Electrical Insulating Film is…
Get ACTiV This Autumn With Mitsubishi
MMAL vice-president of sales, Anthony Casey, said the ACTiV range builds on MMAL’s reputation for delivering value-packed vehicles at affordable prices.
“ACTiV variants offer all the style, comfort and safety features you expect from a Mitsubishi with a number of extras, making them outstanding value,” Casey said.
Based on the ES model, Lancer ACTiV boasts sportier lines thanks to the addition of a Ralliart front bumper and grille, 16-inch alloy…
